Replies to post #279313 on Avid Bioservices Inc (CDMO)

[goodJohnhunting]

We shall see, muaybe PS targeting provides 109%+ better MOS and those Docetaxel arms will never likely never outperform again unless matched with PS Targeting

109%? How can that be with docetaxel, if the data mining has proved 70% less than placebo??. Also, it's been admitted that chemo is not a good combo for antiPs.. That has been an arguement of mine as well, how is it that exposing more immunosuppressive PS through the use of chemo provides more Bavi efficacy??

Here's a quote of mine for reference:

And what about the Chemo Combos that we've been force fed? This is fundamentally flawed, IMO. Inhibiting the immune system in order to gain more PS? Think about that.. more immunosuppressive PS in hopes to dock more Bavituximab? It should have been less is more, not more is better.. And we've, they've known what the data mining has told us years ago, and that is BINDING IS WEAK.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=126143864

So will chemo

All the best,
John